Penumbra, Inc. (PEN) earnings
PEN earnings moved a median of +0.26% by the close. Quarterly and annual PEN reports and results, each read against the price at its own news timestamp. Back to the PEN overview →
29 measured PEN earnings events.
Where these PEN earnings landedvs 29 measured PEN earnings reactions
| Middle 50% of PEN earnings reactions | -0.29% to +1.00% |
|---|---|
| Median reaction (to close) | +0.26% |
| Measured reactions | 29 |
Point-in-time · zero look-ahead
Half of the 29 PEN earnings events with a measured close landed between -0.29% and +1.00%; 62% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Penumbra Inc For: Jun 30 | SEC filing · Form 10-Q | +0.11% | +0.72% | |
| Penumbra, Inc. Reports Second Quarter 2026 Financial Results | Press release | +0.11% | +0.72% | |
| Form 10-Q Penumbra Inc For: Mar 31 | SEC filing · Form 10-Q | +0.74% | +0.26% | |
| Penumbra, Inc. Reports First Quarter 2026 Financial Results | Press release | +0.74% | +0.26% | |
| Form 10-K Penumbra Inc For: Dec 31 | SEC filing · Form 10-K | -0.01% | -0.23% | |
| Form 10-Q Penumbra Inc For: Sep 30 | SEC filing · Form 10-Q | +1.20% | +0.01% | |
| Penumbra, Inc. Reports Third Quarter 2025 Financial Results | Press release | +1.20% | +0.01% | |
| Penumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025 | Press release | -0.65% | +0.94% | |
| Form 10-Q Penumbra Inc For: Jun 30 | SEC filing · Form 10-Q | -2.60% | +0.96% | |
| Penumbra, Inc. Reports Second Quarter 2025 Financial Results | Press release | -2.60% | +0.96% | |
| Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025 | Press release | -0.40% | -0.10% | |
| Form 10-Q Penumbra Inc For: Mar 31 | SEC filing · Form 10-Q | -3.71% | -0.58% | |
| Penumbra, Inc. Reports First Quarter 2025 Financial Results | Press release | -3.71% | -0.58% | |
| Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025 | Press release | +0.00% | -0.42% | |
| Form 10-K Penumbra Inc For: Dec 31 | SEC filing · Form 10-K | +0.04% | +2.93% | |
| Penumbra, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for February 18, 2025 | Press release | -0.45% | +3.15% | |
| Form 10-Q Penumbra Inc For: Sep 30 | SEC filing · Form 10-Q | +1.61% | +6.50% | |
| Penumbra, Inc. Reports Third Quarter 2024 Financial Results | Press release | +1.61% | +6.50% | |
| Penumbra, Inc. Schedules Third Quarter 2024 Earnings Release and Conference Call for October 30, 2024 | Press release | +0.00% | +1.46% | |
| Form 10-Q Penumbra Inc For: Jun 30 | SEC filing · Form 10-Q | +6.17% | +12.89% | |
| Penumbra, Inc. Reports Second Quarter 2024 Financial Results | Press release | +6.17% | +12.89% | |
| Penumbra, Inc. Schedules Second Quarter 2024 Earnings Release and Conference Call for July 30, 2024 | Press release | -0.61% | +0.62% | |
| Form 10-Q Penumbra Inc For: Mar 31 | SEC filing · Form 10-Q | +2.00% | -1.37% | |
| Penumbra, Inc. Reports First Quarter 2024 Financial Results | Press release | +2.00% | -1.37% | |
| Penumbra, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024 | Press release | +0.00% | +1.00% | |
| Form 10-K Penumbra Inc For: Dec 31 | SEC filing · Form 10-K | +0.53% | -0.36% | |
| Penumbra, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 22, 2024 | Press release | +0.00% | -0.67% | |
| Form 10-Q Penumbra Inc For: Sep 30 | SEC filing · Form 10-Q | +1.23% | -0.29% | |
| Penumbra, Inc. Reports Third Quarter 2023 Financial Results | Press release | +1.23% | -0.29% |
Keep exploring
More PEN: analyst actions → · SEC filings → · PEN overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| RITTER PHARMACEUTICALS (RTTR) | 374 | -0.61% | 37% |
| MIRAGEN THERAPEUTICS INC (MGEN) | 369 | -0.39% | 39% |
| Kura Oncology, Inc. (KURA) | 368 | -0.13% | 49% |
| Arcus Biosciences, Inc. (RCUS) | 368 | -0.09% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.